Skip to main content
logo
Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.680
+0.310 (9.20%)
At close: Nov 6, 2026, 4:00 PM EST
3.680
0.00 (0.00%)
Pre-market: Nov 9, 2026, 5:43 AM EST

Immuneering Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.322.08
Revenue Growth
-----84.76%-10.02%
Gross Profit
----0.160.93
Operating Income
-73.88-59.38-64.07-58.41-51.74-33.89
Net Income
-66.5-56.02-61.04-53.47-50.51-33.54
Earnings Per Share
-1.03-1.27-2.04-1.88-1.91-2.46
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
166.12217.0136.1485.67105.52150.2
Total Debt
3.533.824.164.464.845.36
Net Cash (Debt)
162.58213.1931.9881.2100.68144.83
Net Cash Growth
-27.30%566.60%-60.61%-19.35%-30.48%297.13%
Net Cash Per Share
2.514.841.072.863.8210.64

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-61.56-45.34-55-48.97-44.1-30.85
Capital Expenditures
-0.25-0.14-0.08-0.34-0.74-0.06
Free Cash Flow
-61.81-45.49-55.08-49.31-44.84-30.91
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
----50.11%44.56%
Operating Margin
-----16325.77%-1629.17%
Pretax Margin
-----15937.29%-1627.11%
Profit Margin
-----15937.29%-1612.33%
FCF Margin
-----14148.44%-1486.17%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
----404.05204.62